Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy

描述(申请人提供)：癌症治疗中的抗血管生成方法在临床前小鼠模型中显示出巨大的潜力，但到目前为止这种潜力还没有完全实现。 在人类癌症治疗中。这次为期两天的会议名为“针对血管内皮生长因子在癌症治疗中的肿瘤血管生成”，将由纽约科学院于2014年6月19-20日在纽约市举行。会议将探讨我们对影响现有抗血管生成癌症疗法疗效的机制的理解，包括正在进行验证的生物标记物的讨论，这些生物标记物可能预测耐药性和总体临床结果，目的是改进现有的治疗方法，并开发新的抗肿瘤血管生成策略。预计这次活动将召集250名与会者，包括学术界、工业界和政府的基础科学家和临床研究人员、肿瘤学家、制药战略家和监管专家。这次会议的三个中心目标是：(I)通过演讲、主题演讲、互动辩论和网络活动提供一个中立的论坛，讨论血管生成靶向癌症治疗的当前障碍和新兴创新方法，如固有和获得性耐药、代偿性血管生成信号、血管正常化、免疫调节、肿瘤类型、分期和环境相关的药物反应性、预测反应性和耐药性的生物标记物、药物安全性以及提高疗效的联合治疗方法；(Ii)通过简短的演讲、海报介绍/奖品、旅行奖学金、职业指导活动和折扣登记，展示和鼓励职业早期、女性和代表性不足的少数群体研究人员的参与；以及(Iii)促进来自所有部门的国际研究人员之间的合作，以促进将研究转化为更安全和更有效的癌症治疗方法。会议的目标与国家癌症研究所(NCI)的使命非常一致，即支持与癌症相关的基础科学和临床学科的教育，支持癌症控制的研究项目，并鼓励行业的癌症研究。此外，NCI收集和传播癌症信息的具体目标将通过在纽约科学院年鉴上发表一份会议后、持久、开放获取、符合第508条的会议报告来实现，该报告将向全球研究和医学界分发会议上交换的科学知识和思想。考虑到在不同的研究领域(如血管形成和免疫反应)和不同的科学方法(如动物模型和人体临床试验)中出现了大量新数据，这次会议尤其及时。因此，在所有血管生成利益相关者之间协作检查这一新信息对于指导该领域的研究具有重要价值--特别是关于潜在的创新治疗方法，如规避耐药性的方法和用于识别有反应的患者的生物标记物的开发。

DESCRIPTION (provided by applicant): Anti-angiogenic approaches in cancer therapy show great potential in preclinical mouse models, yet to date this potential has not been fully realized in human cancer therapy. This 2-day conference titled, "Targeting VEGF- mediated Tumor Angiogenesis in Cancer Therapy," will be presented by the New York Academy of Sciences on June 19-20, 2014, in New York City. The conference will explore our understanding of the mechanisms impacting the efficacy of existing anti-angiogenic cancer therapeutics, including discussions on biomarkers undergoing validation that may predict resistance and overall clinical outcome, with the goals of improving current treatments and developing new anti-angiogenic strategies for cancer. It is anticipated that this event will convene 250 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; oncologists; pharmaceutical strategists; and regulatory experts. The three central aims of this conference are to: (i) provide a neutral forum through lectures, a keynote presentation, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to angiogenesis-targeted cancer therapy, such as inherent and acquired resistance, compensatory angiogenic signaling, vascular normalization, immune modulation, tumor-type, -stage and -environment related drug responsiveness, biomarkers to predict responsiveness and resistance, drug safety, and combination therapy approaches for improved efficacy; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations/prizes, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboration among international investigators from all sectors to promote the translation of research into safer and more efficient cancer therapeutics. The conference goals align well with the mission of the National Cancer Institute (NCI) to support education in fundamental sciences and clinical disciplines relating to cancer, champion research projects in cancer control, and encourage cancer research by industry. In addition, the NCI's specific goal of collecting and disseminating information on cancer will be met through the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. This conference is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., blood vessel formation and immune response) and from varied scientific approaches (e.g., animal models and human clinical trials). A collaborative examination of this new information among all angiogenesis stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential innovative therapeutic approaches, such as ways to circumvent resistance and the development of biomarkers for identifying responsive patients.